Otsuka Holdings Co., Ltd.
Completion of Rolling Submission of sBLA for IgA Nephropathy Treatment VOYXACT® (Cibeplernimab) in the United States
Announced completion of the rolling submission of the US sBLA for VOYXACT. Stated there is currently no change to the consolidated earnings forecast for the fiscal year ending December 2026 and emphasized positioning VOYXACT as a long-term growth driver.
Key Figures
- Progress in VOYXACT approval process (completion of rolling sBLA submission)
- No change to consolidated earnings forecast for FY ending December 2026
- Positioning VOYXACT as a core medium- to long-term growth driver
AI要約
Overview of the News
Otsuka Holdings Co., Ltd.'s wholly owned subsidiary Otsuka Pharmaceutical's U.S. subsidiary OPDC announced that it has completed the rolling submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration for VOYXACT (cibeplernimab), a treatment for IgA nephropathy. While there is currently no change to the consolidated earnings forecast for the fiscal year ending December 2026, the company positions VOYXACT as one of the products driving medium- to long-term growth and regards this progress as an important development that can enhance corporate value.
Impact on Investors and Outlook
The current disclosure leaves short-term financial impact unclear, but emphasizes that approval progress for VOYXACT supports long-term growth. Completion of the rolling sBLA submission outlines a path to market expansion and implies potential revenue contribution upon approval; however, no specific sales forecasts or launch timelines are provided at this time. The explicit statement that there is no change to the consolidated earnings forecast for fiscal 2026 suggests limited near-term impact.
Otsuka Holdings Co., Ltd.
Company overview · Stock price · Financial data · All IR
